Business Context and Reporting Period
Company: Atyr Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2023
Context: The filing addresses the closure of Silicon Valley Bank (SVB) and the appointment of the FDIC as receiver, providing an update on the Company's exposure to the institution.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to liquidity exposure:
- SVB Exposure: As of March 10, 2023, the Company holds less than 2% of its current cash, cash equivalents, restricted cash, and available-for-sale investments with Silicon Valley Bank.
Material Changes
The filing does not report material changes to the Company's financial results or operations compared to prior periods. The sole material event disclosed is the external banking crisis involving SVB and the Company's confirmation of minimal exposure.
Guidance, Outlook, and Risks
Risk Disclosure: The Company acknowledges the risk associated with the SVB closure but mitigates concern by quantifying its exposure as less than 2% of total liquid assets.
Management Commentary: The disclosure is provided under Regulation FD to ensure fair disclosure of the Company's position regarding the SVB event.
Unusual Items: The filing notes that the information provided is not deemed "filed" for liability purposes under Section 18 of the Exchange Act and shall not be incorporated by reference into other registration statements.
Investor Verification Checklist
- Verify the total amount of cash and cash equivalents held by Atyr Pharma as of the most recent 10-Q or 10-K to calculate the absolute dollar value of the <2% SVB exposure.
- Confirm whether the FDIC has announced a resolution plan for SVB deposits that impacts the Company's specific accounts.
- Review subsequent filings to ensure no additional liquidity constraints have arisen from the SVB event.